OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable'
A new competitor has emerged from stealth to challenge Vertex in cystic fibrosis.
Sionna Therapeutics, a Sanofi Genzyme spinout, announced its launch with $111 million in Series B financing led by OrbiMed. Formed in late 2019, the company is focused solely on developing its pipeline of small molecule treatments that, unlike Vertex’s four currently approved therapies, directly targets the mutated region of CFTR, the protein at the center of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.